UBS Names 8 Midcap Stocks for 2026, Flags Up to 83% Upside

INDUSTRIAL-GOODSSERVICES
Whalesbook Logo
AuthorRiya Kapoor|Published at:
UBS Names 8 Midcap Stocks for 2026, Flags Up to 83% Upside
Overview

UBS Global Research identified eight Indian mid-cap stocks poised for growth in 2026, projecting up to 83% upside. Despite a cautious outlook on the broader segment, with valuations not deeply cheap after a 2025 underperformance, UBS highlights companies with strong earnings visibility and margin improvement potential. The picks span healthcare, hospitality, industrials, and logistics, offering investors specific opportunities beyond market momentum.

UBS Unveils Top Midcap Picks for 2026 Amid Cautious Outlook

UBS Global Research has unveiled its top eight mid-cap stock selections for 2026, identifying significant upside potential, including one with an 83% target. The report acknowledges a recent underperformance by small and mid-cap stocks (SMIDs) in 2025, where the Nifty Midcap 100 gained only 5% and the Nifty Smallcap index declined 7%, contrasting with the Nifty's 10% rise.

Midcaps Face Execution Focus

UBS notes that the "easy phase of midcap gains is over." Future returns will hinge more on company-specific earnings delivery rather than broad market momentum. Despite a recent pullback, SMIDs have delivered stronger five-year compounded returns, largely driven by sustained domestic fund inflows.

Valuations Stabilize, Not Cheap

The brokerage observed that mid-cap valuations corrected in 2025 but are not significantly cheap. The Midcap index now trades near its five-year average one-year-forward PE, a substantial shift from last year's 21% premium. However, these levels do not indicate support for a wide-ranging sector rebound.

UBS's 2026 Midcap Selections

Despite the cautious broader view, UBS has designated eight mid-cap stocks as 'Buy' candidates for 2026, emphasizing earnings visibility, margin strength, and distinct company drivers.

Shaily Engineering Plastics is highlighted as a key beneficiary of generic GLP-1 product demand, with a target price of ₹4,000, suggesting an 83% upside. Max Healthcare Institute offers improved growth visibility due to recent capacity additions, carrying a target of ₹1,475 (45% upside).

Indian Hotels Company maintains a positive outlook from UBS despite hospitality cycle peak concerns, with a target of ₹900 (30% upside). Shyam Metalics and Energy is positioned to gain from rising commodity prices and capacity expansion in value-added products, with a target price of ₹1,350 (68% upside).

Fortis Healthcare is expected to see continued margin improvement from brownfield expansions, targeted at ₹1,150 (29% upside). Astral is set to benefit from demand growth, stable input prices, and margin improvements via backward integration, with a target of ₹1,902.90 (32% upside).

APL Apollo Tubes could experience earnings growth through EBITDA per ton improvement and market share gains, with a target of ₹1,900 (16% upside). Delhivery is anticipated to leverage efficiency gains and pricing power, with its target set at ₹580 (46% upside).

The report concludes that the mid-cap segment's 2026 performance will be execution-dependent, favoring select companies with clear growth and margin expansion paths.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.